Low-cost assays for monitoring HIV infected individuals in resource-limited settings

Use of a combination of CD4 counts and HIV viral load testing in the management of antiretroviral therapy (ART) provides higher prognostic estimation of the risk of disease progression than does the use of either test alone. The standard methods to monitor HIV infection are flow cytometry based for CD4+ T cell count and molecular assays to quantify plasma viral load of HIV. Commercial assays have been routinely used in developed countries to monitor ART. However, these assays require expensive equipment and reagents, well trained operators, and established laboratory infrastructure. These requirements restrict their use in resource-limited settings where people are most afflicted with the HIV-1 epidemic. With the advent of low-cost and/or low-tech alternatives, the possibility of implementing CD4 count and viral load testing in the management of ART in resource-limited settings is increasing. However, an appropriate validation should have been done before putting them to use for patient testing.

[1]  F. González-Sastre,et al.  The Predictive Value of Several Markers in the Progression to Acquired Immunodeficiency Syndrome , 1998, Clinical chemistry and laboratory medicine.

[2]  S. Crowe,et al.  Evaluation of the Cavidi ExaVir Load Assay (Version 3) for Plasma Human Immunodeficiency Virus Type 1 Load Monitoring , 2009, Journal of Clinical Microbiology.

[3]  S. Solomon,et al.  Comparison of Microcapillary Cytometry Technology and Flow Cytometry for CD4+ and CD8+ T-Cell Estimation , 2005, Clinical Diagnostic Laboratory Immunology.

[4]  Z. Fox,et al.  Comparative Evaluation of the ExaVir Load Version 3 Reverse Transcriptase Assay for Measurement of Human Immunodeficiency Virus Type 1 Plasma Load , 2009, Journal of Clinical Microbiology.

[5]  J. Carlin,et al.  Predictive value of CD4 lymphocyte numbers for the development of opportunistic infections and malignancies in HIV-infected persons. , 1991, Journal of acquired immune deficiency syndromes.

[6]  T. Peter,et al.  Accurate CD4 T-cell enumeration and antiretroviral drug toxicity monitoring in primary healthcare clinics using point-of-care testing , 2011, AIDS.

[7]  J. Hocking,et al.  Evaluation of a low cost reverse transcriptase assay for plasma HIV-1 viral load monitoring. , 2005, Current HIV research.

[8]  K. Mandaliya,et al.  In-house HIV-1 RNA real-time RT-PCR assays: principle, available tests and usefulness in developing countries , 2008, Expert review of molecular diagnostics.

[9]  J. Böni,et al.  Quantification of HIV-1 p24 by a highly improved ELISA: an alternative to HIV-1 RNA based treatment monitoring in patients from Abidjan, Côte d'Ivoire. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[10]  K. Pattanapanyasat,et al.  Comparison of 5 Flow Cytometric Immunophenotyping Systems for Absolute CD4+ T-Lymphocyte Counts in HIV-1-Infected Patients Living in Resource-Limited Settings , 2008, Journal of acquired immune deficiency syndromes.

[11]  K. Mayer,et al.  Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. , 2007, Journal of medical microbiology.

[12]  W. Stevens,et al.  African regional external quality assessment for CD4 T‐cell enumeration: Development, outcomes, and performance of laboratories , 2008, Cytometry. Part B, Clinical cytometry.

[13]  J. V. van Oosterhout,et al.  Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria , 2009, Tropical medicine & international health : TM & IH.

[14]  T. Flanigan,et al.  A Reliable and Inexpensive EasyCD4 Assay for Monitoring HIV-Infected Individuals in Resource-Limited Settings , 2006, Journal of acquired immune deficiency syndromes.

[15]  Cheryl Jennings,et al.  HIV-1 Viral Load Assays for Resource-Limited Settings , 2006, PLoS medicine.

[16]  Robert Oelrichs,et al.  Monitoring of human immunodeficiency virus infection in resource-constrained countries. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  D. Richman,et al.  Pooled Nucleic Acid Testing to Detect Antiretroviral Treatment Failure in Mexico , 2011, Journal of acquired immune deficiency syndromes.

[18]  T. Leitner,et al.  HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasma , 2003, Journal of medical virology.

[19]  J. Böni,et al.  Heat‐mediated immune complex dissociation and enzyme‐linked immunosorbent assay signal amplification render p24 antigen detection in plasma as sensitive as HIV‐1 RNA detection by polymerase chain reaction , 1996, AIDS.

[20]  Roger Detels,et al.  Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.

[21]  M. Egger,et al.  Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring , 2009, AIDS.

[22]  E. Noulsri,et al.  Evaluation of a single‐platform microcapillary flow cytometer for enumeration of absolute CD4+ T‐lymphocyte counts in HIV‐1 infected Thai patients , 2007, Cytometry. Part B, Clinical cytometry.

[23]  V. Calvez,et al.  Evaluation of the use of dried spots and of different storage conditions of plasma for HIV‐1 RNA quantification , 2007, HIV medicine.

[24]  C. Masimirembwa,et al.  Evaluation of the Partec Flow Cytometer against the BD FACSCalibur System for Monitoring Immune Responses of Human Immunodeficiency Virus-Infected Patients in Zimbabwe , 2007, Clinical and Vaccine Immunology.

[25]  B. Jacquemin,et al.  Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV‐infected men are associated with CD4+ T‐lymphocytes , 2004, Immunology and cell biology.

[26]  J. Karon,et al.  Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial , 1999, The Lancet.

[27]  K. Pallangyo,et al.  Evaluation of the FACScount, TRAx CD4 and Dynabeads methods for CD4 lymphocyte determination. , 1996, Journal of immunological methods.

[28]  D. Israelski,et al.  Validation of Microcapillary Flow Cytometry for Community-Based CD4+ T Lymphocyte Enumeration in Remote Burkina Faso , 2010, The open AIDS journal.

[29]  L. Scott,et al.  Evaluation of Two Commercially Available, Inexpensive Alternative Assays Used for Assessing Viral Load in a Cohort of Human Immunodeficiency Virus Type 1 Subtype C-Infected Patients from South Africa , 2005, Journal of Clinical Microbiology.

[30]  P. Hartigan,et al.  Changes in Plasma HIV RNA Levels and CD4+ Lymphocyte Counts Predict Both Response to Antiretroviral Therapy and Therapeutic Failure , 1997, Annals of Internal Medicine.

[31]  K. Pattanapanyasat,et al.  New BD FACSCount™ CD4 reagent system for simultaneous enumeration of percent and absolute CD4 T‐lymphocytes in HIV‐1‐infected pediatric patients , 2008, Cytometry. Part B, Clinical cytometry.

[32]  S. Oka,et al.  Modified Dynabeads Method for Enumerating CD4+ T-Lymphocyte Count for Widespread Use in Resource-Limited Situations , 2005, Journal of acquired immune deficiency syndromes.

[33]  J. Böni,et al.  Quantitative and sensitive detection of immune-complexed and free HIV antigen after boiling of serum. , 1993, Journal of virological methods.

[34]  J. Margolick,et al.  Evaluation of a Low-Cost Method, the Guava EasyCD4 Assay, to Enumerate CD4-Positive Lymphocyte Counts in HIV-Infected Patients in the United States and Uganda , 2006, Journal of acquired immune deficiency syndromes.

[35]  A. Breckenridge,et al.  Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial , 2010, The Lancet.

[36]  S. Mboup,et al.  Multisite Evaluation of a Point-of-Care Instrument for CD4+ T-Cell Enumeration Using Venous and Finger-Prick Blood: The PIMA CD4 , 2011, Journal of acquired immune deficiency syndromes.

[37]  L. Lynen,et al.  Validation of Primary CD4 Gating as an Affordable Strategy for Absolute CD4 Counting in Cambodia , 2006, Journal of acquired immune deficiency syndromes.

[38]  L. Lynen,et al.  Monitoring for treatment failure in patients on first-line antiretroviral treatment in resource-constrained settings , 2010, Current opinion in HIV and AIDS.

[39]  M. Vray,et al.  Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa , 2005, AIDS.

[40]  W. Göhde,et al.  Affordable CD4+ T‐cell counts on ‘single‐platform’ flow cytometers I. Primary CD4 gating , 2000, British journal of haematology.

[41]  B. Clotet,et al.  Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions , 2004, Journal of Clinical Microbiology.

[42]  G. Janossy,et al.  Large‐scale affordable Panleucogated CD4+ testing with proactive internal and external quality assessment: In support of the South African national comprehensive care, treatment and management programme for HIV and AIDS , 2008, Cytometry. Part B, Clinical cytometry.

[43]  M. Mine,et al.  Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. , 2009, Journal of virological methods.

[44]  P. Campbell,et al.  Decrease in CD4 lymphocyte counts with rest; implications for the monitoring of HIV infection , 1997, International journal of STD & AIDS.

[45]  M. Kazatchkine,et al.  Successful implementation of a low-cost method for enumerating CD4+ T lymphocytes in resource-limited settings: the ANRS 12–26 study , 2003, AIDS (London).

[46]  J. Böni,et al.  Simple monitoring of antiretroviral therapy with a signal‐amplification‐boosted HIV‐1 p24 antigen assay with heat‐denatured plasma , 1997, AIDS.

[47]  A. Foulkes,et al.  Low-Cost HIV-1 Diagnosis and Quantification in Dried Blood Spots by Real Time PCR , 2009, PloS one.

[48]  W. Paxton,et al.  Use of Dried Spots of Whole Blood, Plasma, and Mother's Milk Collected on Filter Paper for Measurement of Human Immunodeficiency Virus Type 1 Burden , 2007, Journal of Clinical Microbiology.

[49]  D. Katzenstein,et al.  Affordable flow cytometry for enumeration of absolute CD4+ T-lymphocytes to identify subtype C HIV-1 infected adults requiring antiretroviral therapy (ART) and monitoring response to ART in a resource-limited setting , 2006, Journal of Translational Medicine.

[50]  R. Paranjape,et al.  Comparison of capillary based microflurometric assay for CD4+ T cell count estimation with dual platform Flow cytometry , 2006, AIDS research and therapy.

[51]  T. Leitner,et al.  Improved HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasma , 2005, Journal of medical virology.

[52]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[53]  D. Böhning,et al.  Comparison of two alternative methods for CD4+ T‐cell determination (Coulter manual CD4 count and CyFlow) against standard dual platform flow cytometry in Uganda , 2006, Cytometry. Part B, Clinical cytometry.

[54]  R. Bosch,et al.  Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[55]  S. Solomon,et al.  Effective evaluation of novel low-cost CD4 monitoring assays. , 2006, Journal of immunological methods.

[56]  Kenneth H Mayer,et al.  An Inexpensive, Simple, and Manual Method of CD4 T-Cell Quantitation in HIV-Infected Individuals for Use in Developing Countries , 2004, Journal of acquired immune deficiency syndromes.

[57]  J. Hogan,et al.  Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[58]  Deborah K Glencross,et al.  A North American multilaboratory study of CD4 counts using flow cytometric panleukogating (PLG): A NIAID‐DAIDS Immunology Quality Assessment Program Study , 2008, Cytometry. Part B, Clinical cytometry.

[59]  E. Noulsri,et al.  A multicenter evaluation of the PanLeucogating method and the use of generic monoclonal antibody reagents for CD4 enumeration in HIV‐infected patients in Thailand , 2005, Cytometry. Part B, Clinical cytometry.

[60]  Trevor Peter,et al.  Evaluation of the PIMA Point-of-Care CD4 Analyzer in VCT Clinics in Zimbabwe , 2010, Journal of acquired immune deficiency syndromes.

[61]  John T McDevitt,et al.  A Microchip CD4 Counting Method for HIV Monitoring in Resource-Poor Settings , 2005, PLoS medicine.

[62]  R Zachariah,et al.  The Partec CyFlow Counter could provide an option for CD4+ T-cell monitoring in the context of scaling-up antiretroviral treatment at the district level in Malawi. , 2006, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[63]  M. Tanner,et al.  Dried-Plasma Transport Using a Novel Matrix and Collection System for Human Immunodeficiency Virus and Hepatitis C Virus Virologic Testing , 2009, Journal of Clinical Microbiology.

[64]  W. Levine,et al.  Evaluation of a New Single-Parameter Volumetric Flow Cytometer (CyFlowgreen) for Enumeration of Absolute CD4+ T Lymphocytes in Human Immunodeficiency Virus Type 1-Infected Thai Patients , 2005, Clinical Diagnostic Laboratory Immunology.

[65]  V. Miller,et al.  Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings , 2008, Current opinion in HIV and AIDS.

[66]  G. Aldrovandi,et al.  Multicenter Evaluation of Use of Dried Blood and Plasma Spot Specimens in Quantitative Assays for Human Immunodeficiency Virus RNA: Measurement, Precision, and RNA Stability , 2003, Journal of Clinical Microbiology.

[67]  K. Pattanapanyasat,et al.  Performance Evaluation of the Alere PIMA CD4 Test for Monitoring HIV-Infected Individuals in Resource-Constrained Settings , 2011, Journal of acquired immune deficiency syndromes.

[68]  S. Crowe,et al.  HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China. , 2010, Diagnostic microbiology and infectious disease.

[69]  V. Soriano,et al.  Evaluation of performance across the dynamic range of the Abbott RealTime HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. , 2007, Journal of virological methods.

[70]  Á. Pascual,et al.  Comparison of an Assay Using Signal Amplification of the Heat-Dissociated p24 Antigen with the Roche Monitor Human Immunodeficiency Virus RNA Assay , 2002, Journal of Clinical Microbiology.

[71]  M. Peeters,et al.  Efficiencies of Four Versions of the AMPLICOR HIV-1 MONITOR Test for Quantification of Different Subtypes of Human Immunodeficiency Virus Type 1 , 1999, Journal of Clinical Microbiology.

[72]  A. Abayomi,et al.  Performance of the Panleucogating protocol for CD4+ T cell enumeration in an HIV dedicated laboratory facility in Barbados , 2008, Cytometry. Part B, Clinical cytometry.

[73]  E. Katabira,et al.  Scaling up antiretroviral treatment in resource-limited settings: successes and challenges , 2007, AIDS.

[74]  S. Crowe,et al.  Assessment of the Low-Cost Cavidi ExaVir Load Assay for Monitoring HIV Viral Load in Pediatric and Adult Patients , 2009, Journal of acquired immune deficiency syndromes.

[75]  J. Eron,et al.  HIV-1 viral load and phenotypic antiretroviral drug resistance assays based on reverse transcriptase activity in comparison to amplification based HIV-1 RNA and genotypic assays. , 2010, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.